scholarly journals COST-EFFECTIVENESS OF PULSE OXIMETRY SCREENING FOR CRITICAL CONGENITAL HEART DEFECTS IN ONTARIO

2018 ◽  
Vol 23 (suppl_1) ◽  
pp. e17-e18
Author(s):  
Amit Mukerji ◽  
Amy Shafey ◽  
Amish Jain ◽  
Eyal Cohen ◽  
Prakeshkumar Shah ◽  
...  

Abstract BACKGROUND Critical congenital heart defects (CCHDs) are a leading cause of morbidity and mortality in newborns, and late diagnosis is associated with mortality and worse outcomes. Many jurisdictions in the USA and elsewhere have implemented routine pulse oximetry screening (POS) for CCHD, which the Canadian Paediatric Society has recently endorsed. Cost-effective analyses in USA and Europe support this approach, but the geographical setting of Ontario in relation to its vast yet sparsely populated regions presents unique challenges with regard to POS implementation. OBJECTIVES To estimate the cost-effectiveness of POS for CCHD in the context of its implementation in Ontario, Canada. DESIGN/METHODS A cost-effectiveness analysis using a Markov model was conducted inputting values derived from an extensive review of literature, and using relevant local databases. The base-case was a 24-hour clinically stable infant born in Ontario. The model employed the healthcare payer (ministry of health) perspective and a life-time horizon. A number of mutually exclusive health states were created, representative of the natural course of CCHDs. The strategies compared were routine pulse oximetry screening versus no screening. Outcome measures, all discounted 1.5%, were quality-adjusted life months (QALMs), lifetime costs, and incremental cost-effectiveness ratios. An a priori threshold of CAD$4,166.67 per QALM (equivalent to CAD$50,000 per quality adjusted life year) was used. Probabilistic sensitivity analysis was conducted using multiple simulations of the model within expected range of variables included in the model. RESULTS The incremental cost of performing POS was estimated to be $27.27 per individual, with a gain of 0.02455 QALMs (Table 1). This yielded an incremental cost-effectiveness ratio (ICER), [Δ Cost / Δ QALMs] of CAD$1,110.79, well below the pre-determined threshold for cost-effectiveness. A probabilistic sensitivity analysis estimated a 93% chance of routine implementation of POS of being cost-effective, with majority of simulated ICERs lying below the threshold of acceptability (Figure 1). CONCLUSION Routine implementation of POS for CCHD is expected to be cost-effective with a high degree of certainty. Further validation of this model may be conducted following implementation to confirm these findings based on local population data.

2015 ◽  
Vol 34 (3) ◽  
pp. 156-164
Author(s):  
Justine Wood

ABSTRACTCritical congenital heart defects (CCHD) are a subset of congenital heart defects that require acute diagnosis and interventions in order to provide optimal health outcomes for newborns. The incidence of infants with CCHD may be as high as six per 1,000 live births.1 Pulse oximetry screening is a new tool used in many nurseries to detect the presence of CCHD with high reliability. This article includes an overview of CCHD and the pulse oximetry screen, including the primary and secondary targets, a test algorithm, reliability, cost-effectiveness, limitations, national recommendations, and implications for nurses, particularly their role in the NICU.


2009 ◽  
Vol 98 (4) ◽  
pp. 682-686 ◽  
Author(s):  
Alf Meberg ◽  
Andreas Andreassen ◽  
Leif Brunvand ◽  
Trond Markestad ◽  
Dag Moster ◽  
...  

2021 ◽  
Vol 103-B (12) ◽  
pp. 1783-1790
Author(s):  
Spencer Montgomery ◽  
Jonathan Bourget-Murray ◽  
Daniel Z. You ◽  
Leo Nherera ◽  
Amir Khoshbin ◽  
...  

Aims Total hip arthroplasty (THA) with dual-mobility components (DM-THA) has been shown to decrease the risk of dislocation in the setting of a displaced neck of femur fracture compared to conventional single-bearing THA (SB-THA). This study assesses if the clinical benefit of a reduced dislocation rate can justify the incremental cost increase of DM-THA compared to SB-THA. Methods Costs and benefits were established for patients aged 75 to 79 years over a five-year time period in the base case from the Canadian Health Payer’s perspective. One-way and probabilistic sensitivity analysis assessed the robustness of the base case model conclusions. Results DM-THA was found to be cost-effective, with an estimated incremental cost-effectiveness ratio (ICER) of CAD $46,556 (£27,074) per quality-adjusted life year (QALY). Sensitivity analysis revealed DM-THA was not cost-effective across all age groups in the first two years. DM-THA becomes cost-effective for those aged under 80 years at time periods from five to 15 years, but was not cost-effective for those aged 80 years and over at any timepoint. To be cost-effective at ten years in the base case, DM-THA must reduce the risk of dislocation compared to SB-THA by at least 62%. Probabilistic sensitivity analysis showed DM-THA was 58% likely to be cost-effective in the base case. Conclusion Treating patients with a displaced femoral neck fracture using DM-THA components may be cost-effective compared to SB-THA in patients aged under 80 years. However, future research will help determine if the modelled rates of adverse events hold true. Surgeons should continue to use clinical judgement and consider individual patients’ physiological age and risk factors for dislocation. Cite this article: Bone Joint J 2021;103-B(12):1783–1790.


Author(s):  
Rachael Powell ◽  
Helen M Pattison ◽  
Abhay Bhoyar ◽  
Alexandra T Furmston ◽  
Lee J Middleton ◽  
...  

The Lancet ◽  
2011 ◽  
Vol 378 (9793) ◽  
pp. 785-794 ◽  
Author(s):  
Andrew K Ewer ◽  
Lee J Middleton ◽  
Alexandra T Furmston ◽  
Abhay Bhoyar ◽  
Jane P Daniels ◽  
...  

Author(s):  
Maria N Plana ◽  
Javier Zamora ◽  
Gautham Suresh ◽  
Luis Fernandez-Pineda ◽  
Shakila Thangaratinam ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document